Edmund Scott Kopetz, M.D., Ph.D., FACP

Peer-Reviewed Articles

1. Lin SH, Raju GS, Huff C, Ye Y, Gu J, Chen JS, Hildebrandt MAT, Liang H, Menter DG, Morris J, Hawk E, Stroehlein JR, Futreal A, Kopetz S, Mishra L, Wu X. The somatic mutation landscape of premalignant colorectal adenoma. Gut 67(7):1299-1305, 2018. e-Pub 2017. PMID: 28607096.
2. Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 23(15):4146-4154, 2017. e-Pub 2017. PMID: 28280091.
3. Leung ML, Davis A, Gao R, Casasent A, Wang Y, Sei E, Vilar E, Maru D, Kopetz S, Navin NE. Single-cell DNA sequencing reveals a late-dissemination model in metastatic colorectal cancer. Genome Res 27(8):1287-1299, 2017. e-Pub 2017. PMID: 28546418.
4. Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res 23(14):3657-3666, 2017. e-Pub 2017. PMID: 28096270.
5. Mehrotra M, Singh RR, Chen W, Huang RSP, Almohammedsalim AA, Barkoh BA, Simien CM, Hernandez M, Behrens C, Patel KP, Routbort MJ, Broaddus RR, Medeiros LJ, Wistuba II, Kopetz S, Luthra R. Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. J Mol Diagn 19(4):514-524, 2017. e-Pub 2017. PMID: 28506684.
6. Kumar R, Herold JL, Schady D, Davis J, Kopetz S, Martinez-Moczygemba M, Murray BE, Han F, Li Y, Callaway E, Chapkin RS, Dashwood WM, Dashwood RH, Berry T, Mackenzie C, Xu Y. Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development. PLoS Pathog 13(7):e1006440, 2017. e-Pub 2017. PMID: 28704539.
7. Park IJ, You YN, Skibber JM, Rodriguez-Bigas MA, Das P, Eng C, Kopetz S, Wolff RA, Crane CH, Krishnan S, Minsky B, Hu CY, Nguyen S, Chang GJ. Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. Am J Clin Oncol 40(3):277-282, 2017. e-Pub 2016. PMID: 27028350.
8. Yamashita S, Odisio BC, Huang SY, Kopetz SE, Ahrar K, Chun YS, Conrad C, Aloia TA, Gupta S, Harmoush S, Hicks ME, Vauthey JN. Embryonic origin of primary colon cancer predicts survival in patients undergoing ablation for colorectal liver metastases. Eur J Surg Oncol 43(6):1040-1049, 2017. e-Pub 2017. PMID: 28187878.
9. Arango NP, Brusco L, Mills Shaw KR, Chen K, Eterovic AK, Holla V, Johnson A, Litzenburger B, Khotskaya YB, Sanchez N, Bailey A, Zheng X, Horombe C, Kopetz S, Farhangfar CJ, Routbort M, Broaddus R, Bernstam EV, Mendelsohn J, Mills GB, Meric-Bernstam F. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget 8(26):41806-41814, 2017. e-Pub 2017. PMID: 28415679.
10. Sundar R, Hong DS, Kopetz S, Yap TA. Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. Cancer Discov 7(6):558-560, 2017. PMID: 28576843.
11. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget 8(24):39268-39279, 2017. PMID: 28424412.
12. Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, Qiao W, Wang H, Morris J, Wolff RA, Overman MJ. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. Cancer 123(6):1011-1017, 2017. e-Pub 2016. PMID: 27859010.
13. Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Bryan Rumble R, Temple-Smolkin R, B Ventura C, Nowak JA. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med 141(5):625-657, 2017. e-Pub 2017. PMID: 28165284.
14. Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35(13):JCO2016719807, 2017. e-Pub 2017. PMID: 28165299.
15. Odisio BC, Yamashita S, Huang SY, Harmoush S, Kopetz SE, Ahrar K, Shin Chun Y, Conrad C, Aloia TA, Gupta S, Hicks ME, Vauthey JN. Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. Br J Surg 104(6):760-768, 2017. e-Pub 2017. PMID: 28240361.
16. Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. J Oncol Pract 13(5):JOP2017022152, 2017. e-Pub 2017. PMID: 28350513.
17. Rigoutsos I, Lee SK, Nam SY, Anfossi S, Pasculli B, Pichler M, Jing Y, Rodriguez-Aguayo C, Telonis AG, Rossi S, Ivan C, Catela Ivkovic T, Fabris L, Clark PM, Ling H, Shimizu M, Redis RS, Shah MY, Zhang X, Okugawa Y, Jung EJ, Tsirigos A, Huang L, Ferdin J, Gafà R, Spizzo R, Nicoloso MS, Paranjape AN, Shariati M, Tiron A, Yeh JJ, Teruel-Montoya R, Xiao L, Melo SA, Menter D, Jiang ZQ, Flores ER, Negrini M, Goel A, Bar-Eli M, Mani SA, Liu CG, Lopez-Berestein G, Berindan-Neagoe I, Esteller M, Kopetz S, Lanza G, Calin GA. N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome Biol 18(1):98, 2017. e-Pub 2017. PMID: 28535802.
18. Sarshekeh AM, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One 12(3):e0173345, 2017. e-Pub 2017. PMID: 28267766.
19. Khan M, Korphaisarn K, Saif A, Foo WC, Kopetz S. Early-Onset Signet-Ring Cell Adenocarcinoma of the Colon: A Case Report and Review of the Literature. Case Rep Oncol Med 2017:2832180, 2017. e-Pub 2017. PMID: 28326211.
20. Arcaroli JJ, Tai WM, McWilliams R, Bagby S, Blatchford PJ, Varella-Garcia M, Purkey A, Quackenbush KS, Song EK, Pitts TM, Gao D, Lieu C, McManus M, Tan AC, Zheng X, Zhang Q, Ozeck M, Olson P, Jiang ZQ, Kopetz S, Jimeno A, Keysar S, Eckhardt G, Messersmith WA. A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. Int J Cancer 138(1):195-205, 2016. e-Pub 2015. PMID: 26152787.
21. Lee MS, Kopetz S. Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer. Clin Colorectal Cancer 14(4):203-18, 2015. e-Pub 2015. PMID: 26077270.
22. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S. The Consensus Molecular Subtypes of Colorectal Cancer. Nat Med 21(11):1350-6, 2015. e-Pub 2015. PMID: 26457759.
23. Shah MS, Fogelman DR, Raghav KP, Heymach JV, Tran HT, Jiang ZQ, Kopetz S, Daniel CR. Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. Cancer 121(17):2968-75, 2015. e-Pub 2015. PMID: 25975416.
24. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol 33(25):2753-62, 2015. e-Pub 2015. PMID: 26014291.
25. Chang GJ, Kopetz S. Coordination of care in colon cancer. Cancer 121(18):3201-2, 2015. e-Pub 2015. PMID: 26043269.
26. Hecht JR, Douillard JY, Schwartzberg L, Grothey A, Kopetz S, Rong A, Oliner KS, Sidhu R. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treat Rev 41(8):653-9, 2015. e-Pub 2015. PMID: 26220150.
27. Brudvik KW, Kopetz ES, Li L, Conrad C, Aloia TA, Vauthey JN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg 102(10):1175-83, 2015. e-Pub 2015. PMID: 26206254.
28. Reddy SM, Kopetz S, Morris J, Parikh N, Qiao W, Overman MJ, Fogelman D, Shureiqi I, Jacobs C, Malik Z, Jimenez CA, Wolff RA, Abbruzzese JL, Gallick G, Eng C. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Invest New Drugs 33(4):977-84, 2015. e-Pub 2015. PMID: 26062928.
29. Chen T, Sun Y, Ji P, Kopetz S, Zhang W. Topoisomerase IIα in chromosome instability and personalized cancer therapy. Oncogene 34(31):4019-31, 2015. e-Pub 2014. PMID: 25328138.
30. Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst 107(7), 2015. e-Pub 2015. PMID: 25863335.
31. Goswami RS, Patel KP, Singh RR, Meric-Bernstam F, Kopetz ES, Subbiah V, Alvarez RH, Davies MA, Jabbar KJ, Roy-Chowdhuri S, Lazar AJ, Medeiros LJ, Broaddus RR, Luthra R, Routbort MJ. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res 21(11):2644-51, 2015. e-Pub 2015. PMID: 25695693.
32. Mise Y, Kopetz S, Mehran RJ, Aloia TA, Conrad C, Brudvik KW, Taggart MW, Vauthey JN. Is Complete Liver Resection Without Resection of Synchronous Lung Metastases Justified?. Ann Surg Oncol 22(5):1585-92, 2015. e-Pub 2014. PMID: 25373535.
33. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6(14):12809-21, 2015. e-Pub 2015. PMID: 25980577.
34. Morelli MP, Overman MJ, Dasari A, Kazmi SM, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, Morris J, Kee BK, Janku F, Deaton FL, Garrett C, Maru D, Diehl F, Angenendt P, Kopetz S. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26(4):731-6, 2015. e-Pub 2015. PMID: 25628445.
35. Mise Y, Zimmitti G, Shindoh J, Kopetz S, Loyer EM, Andreou A, Cooper AB, Kaur H, Aloia TA, Maru DM, Vauthey JN. RAS Mutations Predict Radiologic and Pathologic Response in Patients Treated with Chemotherapy Before Resection of Colorectal Liver Metastases. Ann Surg Oncol 22(3):834-42, 2015. e-Pub 2014. PMID: 25227306.
36. Atreya CE, Corcoran RB, Kopetz S. Expanded RAS: Refining the Patient Population. J Clin Oncol 33(7):682-5, 2015. e-Pub 2015. PMID: 25584005.
37. Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Eterovic AK. Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. Clin Chem 61(3):544-53, 2015. e-Pub 2015. PMID: 25626406.
38. Bresalier RS, Kopetz S, Brenner DE. Blood-Based Tests for Colorectal Cancer Screening: Do They Threaten the Survival of the FIT Test?. Dig Dis Sci 60(3):664-71, 2015. e-Pub 2015. PMID: 25680874.
39. Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer 112(6):1088-97, 2015. e-Pub 2015. PMID: 25688736.
40. Cabanillas ME, Patel A, Danysh BP, Dadu R, Kopetz S, Falchook G. BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity. Horm Cancer 6(1):21-36, 2015. e-Pub 2014. PMID: 25467940.
41. Kopetz S, Tabernero J, Rosenberg R, Jiang ZQ, Moreno V, Bachleitner-Hofmann T, Lanza G, Stork-Sloots L, Maru D, Simon I, Capellà G, Salazar R. Genomic Classifier ColoPrint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical Factors. Oncologist 20(2):127-33, 2015. e-Pub 2015. PMID: 25561511.
42. Pereira AA, Rego JF, Morris V, Overman MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang ZQ, Hoff PM, Vauthey JN, Vilar E, Maru D, Kopetz S. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer 112(3):424-8, 2015. e-Pub 2014. PMID: 25535726.
43. Fan F, Bellister S, Lu J, Ye X, Boulbes DR, Tozzi F, Sceusi E, Kopetz S, Tian F, Xia L, Zhou Y, Bhattacharya R, Ellis LM. The requirement for freshly isolated human colorectal cancer (CRC) cells in isolating CRC stem cells. Br J Cancer 112(3):539-46, 2015. e-Pub 2014. PMID: 25535733.
44. Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH, Li S. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res 21(4):899-906, 2015. e-Pub 2014. PMID: 25516888.
45. Lee KW, Lee SS, Kim SB, Sohn BH, Lee HS, Jang HJ, Park YY, Kopetz S, Kim SS, Oh SC, Lee JS. Significant Association of oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients. Clin Cancer Res 21(2):357-64, 2015. e-Pub 2014. PMID: 25388162.
46. Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AK. Therapeutic Silencing of KRAS using Systemically Delivered siRNAs. Mol Cancer Ther 13(12):2876-85, 2014. e-Pub 2014. PMID: 25281617.
47. San Lucas FA, Fowler J, Chang K, Kopetz S, Vilar E, Scheet P. Cancer in silico Drug Discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes. Mol Cancer Ther 13(12):3230-40, 2014. e-Pub 2014. PMID: 25349306.
48. Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff MT, Wubbenhorst B, Kim SB, Kopetz S, Ledoux AA, Gopal YN, Pereira CG, Deng W, Lee JS, Nathanson KL, Aldape KD, Prieto VG, Stuart D, Davies MA. Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. Clin Cancer Res 20(21):5537-46, 2014. e-Pub 2014. PMID: 24803579.
49. Morris VK, Lucas FA, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, Kopetz S, Vilar E. Clinicopathologic Characteristics and Gene Expression Analyses of Non-KRAS 12/13, RAS-Mutated Metastatic Colorectal Cancer. Ann Oncol 25(10):2008-14, 2014. e-Pub 2014. PMID: 25009008.
50. Menter DG, Patterson SL, Logsdon CD, Kopetz S, Sood AK, Hawk ET. Convergence of nanotechnology and cancer prevention: are we there yet?. Cancer Prev Res (Phila) 7(10):973-92, 2014. e-Pub 2014. PMID: 25060262.
51. Zhou JH, Rosen D, Andreou A, Brouquet A, Abbott D, Loyer E, Gonzalez-Angulo AM, Kopetz S, Meric-Bernstam F, Kuerer H, Abdalla E, Vauthey JN, Sahin AA, Maru DM. Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. Ann Diagn Pathol 18(5):266-70, 2014. e-Pub 2014. PMID: 25205085.
52. Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer 13(3):164-71, 2014. e-Pub 2014. PMID: 25069797.
53. Aloia TA, Zimmitti G, Conrad C, Gottumukalla V, Kopetz S, Vauthey JN. Return to intended oncologic treatment (RIOT): A novel metric for evaluating the quality of oncosurgical therapy for malignancy. J Surg Oncol 110(2):107-14, 2014. e-Pub 2014. PMID: 24846705.
54. Goldstein J, Tran B, Ensor J, Gibbs P, Wong HL, Wong SF, Vilar E, Tie J, Broaddus R, Kopetz S, Desai J, Overman MJ. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol 25(5):1032-8, 2014. e-Pub 2014. PMID: 24585723.
55. Haynes AB, You YN, Hu CY, Eng C, Kopetz ES, Rodriguez-Bigas MA, Skibber JM, Cantor SB, Chang GJ. Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. Cancer 120(8):1162-70, 2014. e-Pub 2014. PMID: 24474245.
56. Gong J, Xie J, Bedolla R, Rivas P, Chakravarthy D, Freeman JW, Reddick R, Kopetz S, Peterson A, Wang H, Fischer SM, Kumar AP. Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer. Clin Cancer Res 20(5):1259-73, 2014. e-Pub 2014. PMID: 24520096.
57. Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev 33(1):231-69, 2014. e-Pub 2014. PMID: 24696047.
58. Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, You YN, Maru DM, Munsell MF, Clemons MV, Kopetz SE, Garrett CR, Shureiqi I, Delclos ME, Krishnan S, Crane CH. Preoperative Radiation Therapy With Concurrent Capecitabine, Bevacizumab, and Erlotinib for Rectal Cancer: A Phase 1 Trial. Int J Radiat Oncol Biol Phys 88(2):301-5, 2014. e-Pub 2013. PMID: 24315563.
59. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pagès F. Towards the introduction of the Immunoscore in the classification of malignant tumors. J Pathol 232(2):199-209, 2014. e-Pub 2013. PMID: 24122236.
60. Bailey AM, Zhan L, Maru D, Shureiqi I, Pickering CR, Kiriakova G, Izzo J, He N, Wei C, Baladandayuthapani V, Liang H, Kopetz S, Powis G, Guo GL. FXR Silencing in Human Colon Cancer by DNA methylation and KRAS Signaling. Am J Physiol Gastrointest Liver Physiol 306(1):G48-58, 2014. e-Pub 2013. PMID: 24177031.
61. Kopetz S, Morris VK, Parikh N, Overman MJ, Jiang ZQ, Maru D, Elvin P, Gallick G. Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. BMC Cancer 14:660, 2014. e-Pub 2014. PMID: 25208577.
62. Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations. Mol Cancer Ther 12(12):2857-63, 2013. e-Pub 2013. PMID: 24092809.
63. Vauthey JN, Kopetz SE . From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS. Cancer 119(23):4083-5, 2013. e-Pub 2013. PMID: 24105015.
64. Agarwal A, Chang GJ, Hu CY, Taggart M, Rashid A, Park IJ, You YN, Das P, Krishnan S, Crane CH, Rodriguez-Bigas M, Skibber J, Ellis L, Eng C, Kopetz S, Maru DM. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer 119(24):4231-41, 2013. e-Pub 2013. PMID: 24089344.
65. Morris V, Kopetz S. Clinical biomarkers in colorectal cancer. Clin Adv Hematol Oncol 11(12):768-76, 2013. PMID: 24893280.
66. Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A, Curley SA, Aloia TA, Maru DM. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 258(4):619-26; discussion 626-7, 2013. PMID: 24018645.
67. Jiang ZQ, Varadhachary G, Wang X, Kopetz S, Lee JE, Wang H, Shroff R, Katz M, Wolff RA, Fleming J, Overman MJ. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol 24(9):2349-53, 2013. e-Pub 2013. PMID: 23704197.
68. Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gafà R, Song J, Guo Z, Ivan C, Barbarotto E, De Vries I, Zhang X, Ferracin M, Churchman M, van Galen JF, Beverloo BH, Shariati M, Haderk F, Estecio MR, Garcia-Manero G, Patijn GA, Gotley DC, Bhardwaj V, Shureiqi I, Sen S, Multani AS, Welsh J, Yamamoto K, Taniguchi I, Song MA, Gallinger S, Casey G, Thibodeau SN, Le Marchand L, Tiirikainen M, Mani SA, Zhang W, Davuluri RV, Mimori K, Mori M, Sieuwerts AM, Martens JW, Tomlinson I, Negrini M, Berindan-Neagoe I, Foekens JA, Hamilton SR, Lanza G, Kopetz S, Fodde R, Calin GA. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res 23(9):1446-61, 2013. e-Pub 2013. PMID: 23796952.
69. Andreou A, Aloia TA, Brouquet A, Dickson PV, Zimmitti G, Maru DM, Kopetz S, Loyer EM, Curley SA, Abdalla EK, Vauthey JN. Margin Status Remains an Important Determinant of Survival After Surgical Resection of Colorectal Liver Metastases in the Era of Modern Chemotherapy. Ann Surg 257(6):1079-88, 2013. e-Pub 2013. PMID: 23426338.
70. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with P13K inhibition or demethylating agents. Clin Cancer Res 19(3):657-667, 2013. e-Pub 2012. PMID: 23251002.
71. Clary BM, Grothey A, Kopetz S, Marsh RD. Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement. HPB (Oxford) 15(2):116-8, 2013. PMID: 23297722.
72. Overman MJ, Modak J, Kopetz ES, Murthy R, Yao JC, Hicks ME, Abbruzzese JL, Tam AL. Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?. J Clin Oncol 31(1):17-22, 2013. e-Pub 2012. PMID: 23129736.
73. Morris V, Kopetz S. BRAF inhibitors in clinical oncology. F1000Prime Rep 5:11, 2013. e-Pub 2013. PMID: 23585929.
74. Park YY, Lee SS, Lim JY, Kim SC, Kim SB, Sohn BH, Chu IS, Oh SC, Park ES, Jeong W, Kim SS, Kopetz S, Lee JS. Comparison of prognostic genomic predictors in colorectal cancer. PLoS One 8(4):e60778, 2013. e-Pub 2013. PMID: 23626670.
75. Overman MJ, Zhang J, Kopetz S, Davies M, Zhi-Qin J, Stemke-Hale K, Rümmele P, Pilarsky C, Grützmann R, Hamilton S, Hwang R, Abbruzzese JL, Varadhachary G, Broom B, Wang H. Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLoS One 8(6):e65144, 2013. e-Pub 2013. PMID: 23776447.
76. Kopetz S. "Right drug for the right patient". Am Soc Clin Oncol Educ Book 2013:115-20, 2013. PMID: 23714474.
77. Lieu CH, Tran H, Jiang ZQ, Mao M, Overman MJ, Lin E, Eng C, Morris J, Ellis L, Heymach JV, Kopetz S. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One 8(10):e77117, 2013. e-Pub 2013. PMID: 24143206.
78. Park YY, Lee SS, Lim JY, Kim SC, Kim SB, Sohn BH, Chu IS, Oh SC, Park ES, Jeong W, Kim SS, Kopetz S, Lee JS. Correction: Comparison of Prognostic Genomic Predictors in Colorectal Cancer. PLoS One 8(12), 2013. e-Pub 2013. PMID: 24358104.
79. Conte B, Kopetz S. Challenges and strategies for identifying biomarkers for colorectal cancer. Colorectal Cancer 2(6):487-489, 2013. PMID: 25598846.
80. Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz ES, Win S, Kurzrock R. Outcomes in 144 Patients With Colorectal Cancer Treated in a Phase I Clinic: the MD Anderson Cancer Center Experience. Clin Colorectal Cancer 11(4):297-303, 2012. e-Pub 2012. PMID: 22537607.
81. Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA, Vauthey JN. Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic Colorectal Metastases. J Clin Oncol 30(36):4566-72, 2012. e-Pub 2012. PMID: 23150701.
82. Andreou A, Kopetz S, Maru DM, Chen SS, Zimmitti G, Brouquet A, Shindoh J, Curley SA, Garrett C, Overman MJ, Aloia TA, Vauthey JN. Adjuvant Chemotherapy With FOLFOX for Primary Colorectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepatectomy for Metachronous Liver Metastases. Ann Surg 256(4):642-50, 2012. e-Pub 2012. PMID: 22968062.
83. Vauthey JN, Kopetz S, Aloia TA, Andreou A. KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary. Br J Cancer 107(8):1442-3, 2012. e-Pub 2012. PMID: 23018559.
84. Oh SC, Park YY, Park ES, Lim JY, Kim SM, Kim SB, Kim J, Kim SC, Chu IS, Smith JJ, Beauchamp RD, Yeatman TJ, Kopetz S, Lee JS. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut 61(9):1291-8, 2012. e-Pub 2011. PMID: 21997556.
85. Garrett CR, George B, Viswanathan C, Bhadkamkar NA, Wen S, Baladandayuthapani V, You YN, Kopetz ES, Overman MJ, Kee BK, Eng C. Survival Benefit Associated With Surgical Oophorectomy in Patients With Colorectal Cancer Metastatic to the Ovary. Clin Colorectal Cancer 11(3):191-4, 2012. e-Pub 2012. PMID: 22280844.
86. Dai J, Gu J, Huang M, Eng C, Kopetz ES, Ellis LM, Hawk E, Wu X. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis 33(7):1327-31, 2012. e-Pub 2012. PMID: 22505654.
87. Overman MJ, Hu CY, Kopetz ES, Abbruzzese JL, Wolff RA, Chang GJ. A Population-Based Comparison of Adenocarcinoma of the Large and Small Intestine: Insights Into a Rare Disease. Ann Surg Oncol 19(5):1439-45, 2012. e-Pub 2011. PMID: 22187121.
88. Ferrarotto R, Machado K, Mak MP, Shah N, Takahashi TK, Costa FP, Overman MJ, Kopetz S, Hoff PM. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. Eur J Cancer 48(6):820-6, 2012. e-Pub 2012. PMID: 22330318.
89. Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcox ME, Kopetz S, Heimbrook D, Lestini B, Bollag G, Su F. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 72(3):779-89, 2012. e-Pub 2011. PMID: 22180495.
90. Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 10(1):205, 2012. e-Pub 2012. PMID: 23034130.
91. Boonsirikamchai P, Asran MA, Maru DM, Vauthey JN, Kaur H, Kopetz ES, Loyer EM. CT Findings of Response and Recurrence, Independent of Change in Tumor Size, in Colorectal Liver Metastasis Treated With Bevacizumab. AJR Am J Roentgenol 197(6):W1060-6, 2011. PMID: 22109320.
92. Angelo LS, Wu JY, Meng F, Sun M, Kopetz S, McCutcheon IE, Slopis JM, Kurzrock R. Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways. Mol Cancer Ther 10(11):2094-103, 2011. e-Pub 2011. PMID: 21903608.
93. Brouquet A, Overman MJ, Kopetz ES, Maru DM, Loyer EM, Andreou A, Cooper A, Curley SA, Garrett CR, Abdalla EK, Vauthey JN. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?. Cancer 117(19):4484-92, 2011. e-Pub 2011. PMID: 21446046.
94. Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis. Clin Cancer Res 17(19):6130-9, 2011. e-Pub 2011. PMID: 21953501.
95. Ferrarotto R, Pathak P, Maru D, Agarwal A, Overman M, Hoff PM, Kopetz ES. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer 10(3):178-82, 2011. e-Pub 2011. PMID: 21855039.
96. George B, Kopetz ES. Predictive and Prognostic Markers in Colorectal Cancer. (Invited). Curr Oncol Rep 13(3):206-15, 2011. e-Pub 2011. PMID: 21373987.
97. Fogelman DR, Wolff RA, Kopetz ES, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL. Evidence for the Efficacy of Iniparib, a PARP-1 Inhibitor, in BRCA2-associated Pancreatic Cancer. Anticancer Res 31(4):1417-20, 2011. PMID: 21508395.
98. Brouquet A, Abdalla EK, Kopetz ES, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 29(8):1083-90, 2011. e-Pub 2011. PMID: 21263087.
99. Ihle NT, Powis G, Kopetz ES. PI-3-Kinase Inhibitors in Colorectal Cancer (Peer-reviewed Review). Curr Cancer Drug Targets 11(2):190-8, 2011. e-Pub 2010. PMID: 21158718.
100. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz ES, McConkey DJ, Evans DB, Gallick GE. ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma. PLoS One 6(6):e20636, 2011. e-Pub 2011. PMID: 21695188.
101. Silberfein EJ, Kattepogu KM, Hu CY, Skibber JM, Rodriguez-Bigas MA, Feig B, Das P, Krishnan S, Crane C, Kopetz S, Eng C, Chang GJ. Long-term Survival and Recurrence Outcomes Following Surgery for Distal Rectal Cancer. Ann Surg Oncol 17(11):2863-9, 2010. e-Pub 2010. PMID: 20552409.
102. Maru DM, Kopetz S, Boonsirikamchai P, Agarwal A, Chun YS, Wang H, Abdalla EK, Kaur H, Charnsangavej C, Vauthey JN, Loyer EM. Tumor Thickness at the Tumor-normal Interface: A Novel Pathologic Indicator of Chemotherapy Response in Hepatic Colorectal Metastases. Am J Surg Pathol 34(9):1287-1294, 2010. e-Pub 2010. PMID: 20697255.
103. Brouquet A, Mortenson MM, Vauthey JN, Rodriguez-Bigas MA, Overman MJ, Chang GJ, Kopetz S, Garrett C, Curley SA, Abdalla EK. Surgical Strategies for Synchronous Colorectal Liver Metastases in 156 Consecutive Patients: Classic, Combined or Reverse Strategy?. J Am Coll Surg 210(6):934-41, 2010. PMID: 20510802.
104. Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA. Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol 49(4):474-9, 2010. PMID: 20397775.
105. Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, Eng C, Hoff PM, Vauthey JN, Wolff RA, Kopetz S. Oxaliplatin-Mediated Increase in Spleen Size As a Biomarker for the Development of Hepatic Sinusoidal Injury. J Clin Oncol 28(15):2549-2555, 2010. e-Pub 2010. PMID: 20406923.
106. Lieu C, Kopetz S. The SRC family of protein tyrosine kinases: A new and promising target for colorectal cancer therapy. (Peer-reviewed Review). Clin Colorectal Cancer 9(2):89-94, 2010. PMID: 20378502.
107. Vauthey JN, Nordlinger B, Kopetz S, Poston G. Sequenced Chemotherapy and Surgery for Potentially Resectable Colorectal Liver Metastases: A Debate Over Goals of Research and an Approach While the Jury Remains Out. Ann Surg Oncol 17(8):1983-1986, 2010. PMID: 20232164.
108. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. J Clin Oncol 28(3):453-9, 2010. e-Pub 2009. PMID: 20008624.
109. Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer 102(1):144-50, 2010. e-Pub 2009. PMID: 19935793.
110. Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, Curley SA, Abdalla EK, Charnsangavej C, Loyer EM. Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases. JAMA 302(21):2338-2344, 2009. PMID: 19952320.
111. Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, Coulson RL, Charnsangavej C, Vauthey JN, Wolff RA, Kopetz S. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 8(4):225-30, 2009. PMID: 19822514.
112. Kopetz S, Chang G, Overman M, Eng C, Larson DW, Grothey A, Vauthey JN, Sargent D, McWilliams R. Improved Survival in Metastatic Colorectal Cancer is Associated with Sequential Adoption of Hepatic Resection and Improved Chemotherapy. J Clin Oncol 27(22):3677-83, 2009. e-Pub 2009. PMID: 19470929.
113. Herman MP, Kopetz S, Bhosale PR, Eng C, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Delclos ME, Krishnan S, Crane CH, Das P.. Sacral Insufficiency Fractures After Preoperative Chemoradiation for Rectal Cancer: Incidence, Risk Factors, and Clinical Course. Int J Radiat Oncol Biol Phys 74(3):818-23, 2009. e-Pub 2009. PMID: 19147305.
114. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. J Clin Oncol 26(15S):4538, 2009. e-Pub 2009. PMID: 19164203.
115. Rossi S, Kopetz S, Davuluri R, Hamilton SR, Calin GA. MicroRNAs, ultraconserved genes and colorectal cancers. (Invited). Int J Biochem Cell Biol 42(8):1291-1297, 2009. e-Pub 2009. PMID: 19497386.
116. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE.. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69(9):3842-9, 2009. e-Pub 2009. PMID: 19383922.
117. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 16(3):614-22, 2009. e-Pub 2009. PMID: 19130139.
118. Kim MP, Park SI, Kopetz S, Gallick GE.. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res 1(335):249-59, 2009. e-Pub 2008. PMID: 18815812.
119. Chang DZ, Kumar V, Ma Y, Li K, Kopetz S. Individualized Therapies in Colorectal Cancer: KRAS as a Marker for Response to EGFR-targeted Therapy (Invited Editorial). J Hematol Oncol 2(18):18, 2009. e-Pub 2009. PMID: 19386128.
120. Fogelman DR, Kopetz S, Eng C.. Emerging Drugs for Colorectal Cancer (Invited). Expert Opin Emerg Drugs 13(4):629-42, 2008. PMID: 19046131.
121. Blazer DG, Kish U, Maru DM, Kopetz S, Overman M, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover K, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point after Resection of Hepatic Colorectal Metastases. J Clin Oncol 59(33):5344-51, 2008. e-Pub 2008. PMID: 18936472.
122. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, Curley SA, Feig BW.. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26(32):5254-60, 2008. e-Pub 2008. PMID: 18854565.
123. Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbrizzese JL.. Phase I study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest. New Drugs 26(5), 2008. e-Pub 2008. PMID: 18528634.
124. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 113(8):2038-45, 2008. e-Pub 2008. PMID: 18759326.
125. Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL.. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest 26(8):794-9, 2008. PMID: 18798063.
126. Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla EK, Pisters P, Kopetz S, Eng C, Wolff RA.. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer 7(5):338-42, 2008. PMID: 18794067.
127. Hoff PM, Kopetz S, Thomas MB, Langleben A, Rinaldi D, Anthony L, Wolff RA, Lassere Y, Abbruzzese JL. A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. Br J Cancer 99(5):722-6, 2008. e-Pub 2008. PMID: 18728662.
128. Kauffman CR, Mahvash A, Kopetz S, Wolff RA, Ensor J, Wallace MJ. Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy. Cancer 14(10):2283-8, 2008. PMID: 18344210.
129. Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C. Systematic Survey of Therapeutic Trials for Metastatic Colorectal Cancer: Room for Improvement in the Critical Pathway. J Clin Oncol 26(12):2000-5, 2008. PMID: 18421052.
130. Kopetz S, Freitas D, Calabrichi A, Hoff PM. Adjuvant Chemotherapy for Stage II Colon Cancer (Peer-Reviewed Review). Oncology 22(3):260-70, 2008. PMID: 18494354.
131. Dhillon N, Kopetz S, Pei BL, Fabbro ED, Zhang T, Bruera E. Clinical findings of a palliative care consultation team at a comprehensive cancer center. J Palliat Med 11(2):191-7, 2008. PMID: 18333733.
132. Politano S, Overman M, Pathak P, Chadha R, Glover K, Chang DZ, Wolff RA, Hoff PM, Abbruzzese J, Eng C, Kopetz S. Second-Line Chemotherapy Use in Metastatic Colon Cancer Varies by Disease Responsiveness. Clin Colorectal Cancer 1(1):55-9, 2008. PMID: 18279578.
133. Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, Curley SA, Abdalla EK. Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival. J Gastrointest Surg 11(11):1498-1505, 2007. e-Pub 2007. PMID: 17849166.
134. Kopetz S, Jimenez C, Tu SM, Sharma P. Pulmonary arteriovenous fistula in a patient with renal cell carcinoma. Eur Respir J 29(4):813-5, 2006. PMID: 17400880.
135. Kopetz S. Endothelin-1 as a Target For Therapeutic Intervention in Prostate Cancer (Invited). Invest New Drugs 20:173-82, 2002. PMID: 12099577.
136. Kopetz ES, TH Magnuson, MD Duncan, JS Bender, KD Lillemoe, TA Gordon, JL Cameron, JW Harmon. Complications of neglected cholelithiasis account for significant surgical mortality in the elderly. Surg Forum(52):489-91, 2000.
137. Kopetz S, Steele CD, Brandt J, Baker A, Kronberg M, Galik E, Steinberg M, Warren A, Lyketsos CG. Characteristics and outcomes of dementia residents in an assisted living facility. Int J Geriatr Psychiatry 15(7):586-93, 2000. PMID: 10918338.
138. Cheng MD, Nash TM, Kopetz ES. Retrieval of Aerosol Optical Thickness by Means of the Least-Median-Squares Robust Algorithm. Journal of Aerosol Science 30:805-17, 1999.
139. Walczak WJ, Xiao JM, Kopetz ES, Lease K, Grau H, Lee SP, Han MK, and Knutson JR. Golden Ruler: Very Long-Range Resonance Energy Transfer to Surface Plasmon Acceptors. Biophysical Journal, 72:367, 1997.
140. Tran B, Kopetz ES, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. e-Pub 2011. PMID: 21456008.
141. Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, Motta M, Ravarino N, Risio M, Curley SA, Abdalla EK, Capussotti L, Vauthey JN. Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases. Ann Surg Oncol 17(11):2870-6. e-Pub 2010. PMID: 20567921.
142. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Combined BRAF and MEK Inhibition with Dabrafenib and Trametinib in BRAF V600 Mutant Colorectal Cancer. J Clin Oncol. e-Pub 2015. PMID: 26392102.
143. Ling H, Pickard K, Ivan C, Isella C, Ikuo M, Mitter R, Spizzo R, Bullock MD, Braicu C, Pileczki V, Vincent K, Pichler M, Stiegelbauer V, Hoefler G, Almeida MI, Hsiao A, Zhang X, Primrose JN, Packham GK, Liu K, Bojja K, Gafà R, Xiao L, Rossi S, Song JH, Vannini I, Fanini F, Kopetz S, Zweidler-McKay P, Wang X, Ionescu C, Irimie A, Fabbri M, Lanza G, Hamilton SR, Berindan-Neagoe I, Medico E, Mirnezami AH, Calin GA, Nicoloso MS. The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut. e-Pub 2015. PMID: 25804630.
144. Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, Honn KV. Platelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Rev. e-Pub 2017. PMID: 28730545.
145. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. e-Pub 2017. PMID: 28734759.
146. Lam M, Roszik J, Kanikarla-Marie P, Davis JS, Morris J, Kopetz S, Menter DG. The potential role of platelets in the consensus molecular subtypes of colorectal cancer. Cancer Metastasis Rev. e-Pub 2017. PMID: 28681242.
147. Kanikarla-Marie P, Lam M, Menter DG, Kopetz S. Platelets, circulating tumor cells, and the circulome. Cancer Metastasis Rev. e-Pub 2017. PMID: 28667367.
148. Ikoma N, You YN, Bednarski BK, Rodriguez-Bigas MA, Eng C, Das P, Kopetz S, Messick C, Skibber JM, Chang GJ. Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer. J Clin Oncol:JCO2016721464. e-Pub 2017. PMID: 28657814.
149. Long Y, Sanchez-Espiridion B, Lin M, White L, Mishra L, Raju GS, Kopetz S, Eng C, Hildebrandt MAT, Chang DW, Ye Y, Liang D, Wu X. Global and targeted serum metabolic profiling of colorectal cancer progression. Cancer. e-Pub 2017. PMID: 28640361.
150. Janku F, Zhang S, Waters J, Liu L, Huang H, Subbiah V, Hong DS, Karp D, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DD, Zhao Y, Javle M, Kopetz S, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach J, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS. Development and validation of an ultra-deep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer. Clin Cancer Res. e-Pub 2017. PMID: 28536309.
151. Goldstein JB, Wu W, Borras E, Masand G, Cuddy A, Mork ME, Bannon SA, Lynch PM, Rodriguez-Bigas M, Taggart MW, Wu J, Scheet P, Kopetz S, You YN, Vilar E. Can Microsatellite Status of Colorectal Cancer Be Reliably Assessed after Neoadjuvant Therapy?. Clin Cancer Res. e-Pub 2017. PMID: 28522602.
152. Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, Kasi PM, Voss JS, Leal AD, Sun J, Ross J, Ali SM, Hubbard JM, Kipp BR, McWilliams RR, Kopetz S, Wolff RA, Grothey A. Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol:JCO2016714394. e-Pub 2017. PMID: 28486044.
153. Katsiampoura A, Raghav K, Jiang ZQ, Menter DG, Varkaris A, Morelli MP, Manuel S, Wu J, Sorokin AV, Rizi BS, Bristow C, Tian F, Airhart S, Cheng M, Broom BM, Morris J, Overman MJ, Powis G, Kopetz S. Modeling of Patient Derived Xenografts in Colorectal Cancer. Mol Cancer Ther. e-Pub 2017. PMID: 28468778.
154. Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight 2(8). e-Pub 2017. PMID: 28422758.

Invited Articles

1. Kopetz S. Novel Targets for Systemic Therapy of Colorectal Cancer. Clin Adv Hematol Oncol 6(1):38-40, 2008. PMID: 18322439.
2. Kopetz S, Shah AN, Gallick GE. SRC continues aging: current and future clinical directions. Clin Cancer Res 13(24):7232-6, 2007. PMID: 18094400.
3. Kopetz S. Targeting Src and Epidermal Growth Factor Receptor in Colorectal Cancer: Rationale and Progress Into the Clinic. Gastrointestinal Cancer Research 1:S37-41, 2007.
4. Kopetz S, Hoff PM. Cytotoxic chemotherapy for advanced colorectal cancer. Recent advances in management. Oncology (Williston Park) 19(13 Suppl 6):11-7, 2005. PMID: 16502665.
5. Kopetz S, Kim ES. Adjuvant Chemotherapy in Non-Small Cell Lung Cancer. American Journal of Oncology Review (Pulmonary Supplement):1-4, 2005.

Manuals, Teaching Aids, Other Teaching Publications

1. Kopetz ES. Etiology and Management of Bowel Perforation in Patients with Colorectal Cancer” Gastrointestinal Malignancies: Putting Theory Into Practice at M. D. Anderson. M. D. Anderson: Houston, Texas, 2007.

Editorials

1. Davies MA, Kopetz S. Overcoming resistance to MAPK pathway inhibitors. J Natl Cancer Inst 105(1):9-10, 2013. PMID: 23250957.
2. Kopetz S, Lemos R, Powis G. The promise of patient-derived xenografts: the best laid plans of mice and men. Clin Cancer Res 18(19):5160-2, 2012. PMID: 22912394.
3. Morelli MP, Kopetz S. Hurdles and complexities of codon 13 KRAS mutations. J Clin Oncol 30(29):3565-7, 2012. PMID: 22927534.
4. Kopetz S, Abbruzzese J. Barriers to Integrating Gene Profiling for Stage II Colon Cancer. Clinical Cancer Research 15(24), 2009. PMID: 19996205.
5. Eng C, Kopetz S. Commentary: Practice Patterns and Potential Impact on Quality Measurements for a Practicing Physician. Journal of Oncology Practice 5(5):233-5, 2009.
6. Overman M, Kopetz S. Picking the Right Road for Metastatic Colorectal Cancer Patients. Oncology 22(13):1482-3, 2008. PMID: 19227576.
7. Kopetz S, Vauthey JN. Perioperative chemotherapy for resectable hepatic metastases. Lancet 371(9617):963-5, 2008. PMID: 18358910.

Abstracts

1. Lee MS, Clarke C, Jiang ZQ, Manyam GC, Tian F, Lu Y, Morris J, Broom BM, Menter D, Vilar Sanchez E, Shureiqi I, Raghav KPS, Eng C, Chang GJ, Simon I, Bernards R, Mills GB, Overman MJ, Maru DM, Kopetz S. Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups independent of oncogenic mutations. J Clin Oncol 33(suppl 3), 2015.
2. Kopetz S, Litzenburger B, Kinyua W, Sajan B, Subbiah V, Zinner R, Wheler JJ, Hong DS, Tsimberidou AM, Overman MJ, Pagliaro LC, Busaidy NL, Westin SN, Glisson BS, Heymach J, Meric-Bernstam F, Shaw KR, Lee JJ, Broaddus R. Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment. J Clin Oncol 33(suppl), 2015.
3. Overman MJ, Kee BK, Fogelman DR, Eng C, Vilar Sanchez E, Shroff RT, Dasari A, Wolff RA, Morris J, Kopetz S. A phase II study of nab-paclitaxel in refractory CIMP-high metastatic colorectal cancer. J Clin Oncol 33(suppl), 2015.
4. Morelli MP, Overman MJ, Kee BK, Vilar Sanchez E, Morris VK, Fogelman DR, Janku F, Garrett CR, Shureiqi I, Raghav KPS, Eng C, Manuel S, Wolff RA, Eltoukhy H, Lanman RB, Talasaz AA, Kopetz S. Predictors of clonal evolution in metastatic colorectal cancer patients. J Clin Oncol 33(suppl), 2015.
5. Bedard PL, Davies MA, Kopetz S, Flaherty KT, Shapiro G, Luke JJ, Spreafico A, Wu B, Gomez C, Cartot-Cotton S, Mazuir F, Micallef S, Demers B, Juric D. First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737). J Clin Oncol 33(suppl), 2015.
6. Morris VK, Morelli MP, Janku F, Overman MJ, Kee BK, Fogelman DR, Vilar Sanchez E, Shureiqi I, Garrett CR, Raghav KPS, Eng C, Manuel S, Wolff RA, Eltoukhy H, Lanman RB, Talasaz AA, Kopetz S. Clinical utility of a circulating cell-free DNA assay for clinical trial enrollment in refractory metastatic colorectal cancer patients. J Clin Oncol 33(suppl), 2015.
7. Hong DS, Morris VK, El Osta BE, Fu S, Overman MJ, Piha-Paul SA, Subbiah V, Kee BK, Tsimberidou AM, Zinner R, Fogelman DR, Bellido J, Shureiqi I, Meric-Bernstam F, Kopetz S. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers. J Clin Oncol 33(suppl), 2015.
8. Kwatampora L, Clarke C, Silva A, Zorba Y, Williams MD, Broaddus R, Clayman GL, El-Naggar AK, Gagel RF, Grubbs EG, Habra MA, I-Nan Hu M, Jimenez C, Kopetz S, Lee JE, StevSherman SI, Vassilopoulou-Sellin R, Waguespack S, Perrier ND, Busaidy NL. Recurrent parathyroid carcinoma and the need for molecular profiling to aid in prognostication and therapeutics. J Clin Oncol 33(suppl), 2015.
9. Meric-Bernstam F, Brusco L, Daniels MS, Strong LC, Shaw KR, Lu KH, Qi Y, Lara-Guerra H, Litton JK, Zhao H, Eterovic AK, Arun B, Routbort M, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program. J Clin Oncol 33(suppl), 2015.
10. Janku F, Vibat CRT, Falchook GS, Huang HJ, Hong DS, Piha-Paul SA, Subbiah V, Ramzanali NM, Hancock S, Naing A, DaKarp DD, Nitti G, Cabrilo G, Luthra R, Patel SP, Overman MJ, Kopetz S, Erlander MG, Melnikova V, Meric-Bernstam F. Low frequency KRAS G12/13 mutations in urine cell-free (cf) DNA from patients with BRAF V600E-mutant advanced cancers. J Clin Oncol 33(suppl), 2015.
11. Kopetz S, Lemos R, Powis G. The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men. Clinical Cancer Research, 2012.
12. Corcoran RB, Falchook GS, Infante JR, Hamid O, Messersmith WA, Kwak EL, Ryan DP, Kurzrock R, Brenner AA, Luan J, Sun P, Allred AJ, Little SM, Patel L, Kopetz S, Venook AP. BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212). J Clin Oncol 30, 2012.
13. Overman MJ, Eng C, Kee BK, Fogelman DR, Fark C, Hippert R, Holter S, Issa JP, Hamilton SR, Kopetz S. A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer. J Clin Oncol 30, 2012.
14. Chen Z, Overman MJ, Garrett CR, Jiang ZQ, Wolff RA, Abbruzzese JL, Eng C, Kopetz S. Systematic survey of therapeutic trials for metastatic colorectal cancer. J Clin Oncol 30(suppl 4), 2012.
15. Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, Maru D, Munsell MF, Clemons MV, Kopetz S, Garrett CR, Shureiqi I, Krishnan S, Delclos ME, Crane CH. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal adenocarcinoma: A phase I trial. J Clin Oncol 30(suppl 4), 2012.
16. Shah NN, Lieu CH, Ivan C, Overman MJ, Shimizu M, Morris J, Tran H, Heymach J, Calin G, Kopetz S. Prognostic effects of circulating markers of epithelial mesenchymal transition (EMT) in metastatic colorectal cancer patients. J Clin Oncol, 2012.
17. Overman MJ, George B, Kalil K, Ferrarotto R, Eng C, Garrett CR, Loyer E, Hoff PM, Charnsangavej C, Kopetz S. Use of bevacizumab to reduce the rate of oxaliplatin-induced thrombocytopenia and splenomegaly. J Clin Oncol 30(Suppl 4), 2012.
18. Raghav KPS, Kalil K, Ferrarotto R, George B, Eng C, Garrett CR, Loyer E, Hoff PM, Charnsangavej C, Kopetz S, Overman MJ. Effect of bevacizumab on rate of oxaliplatin-induced thrombocytopenia and splenomegaly. J Clin Oncol 30, 2012.
19. Chen ZY, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong DS, Hoff PM, Tran HT, Heymach J, Overman MJ, Kopetz S. Correlation of specific cytokine profiles with high blood neutrophil-to-lymphocyte ratio and outcome in metastatic colorectal cancer. J Clin Oncol 30, 2012.
20. Chang GJ, Park IJ, Eng C, You YN, Kopetz S, Overman MJ, Rodriguez-Bigas MA, Skibber JM. Exploratory analysis of adjuvant chemotherapy benefits after preoperative chemoradiotherapy and radical resection for rectal cancer. J Clin Oncol 30, 2012.
21. Morris VK, Parikh N, Overman MJ, Jiang ZQ, Maru DM, Elvin D, Kopetz S, Gallick GE. Relationship of Src activity and prior oxaliplatin on outcomes after hepatectomy for metastatic colorectal cancer. J Clin Oncol 30, 2012.
22. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey J, Rodriguez-Bigas MA, Curley SA, Feig BW. Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab (BV) for colorectal cancer (CRC) liver metastases. 2007 Gastrointestinal Cancers Symposium, 2012.
23. Mao M, Tsao L, Dayyani F, Gopal V, Nanda Y, Mills G, Bollag G, Davies M, Gallick G, Kopetz S. Resistance to BRAF inhibition in BRAF V600E colorectal cancer is associated with PI3K/AKT activation and hypermethylation. AACR 2011:LB-228, 2011.
24. Lieu CH, Tran HT, Fiorentino S, Jiang Z, Mao M, Overman MJ, Eng C, Ellis LM, Heymach J, Kopetz S. Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer. J Clin Oncol 29((suppl 4; abstr 401)), 2011.
25. Jiang Z, Mehta TR, You YN, Chang GJ, Eng C, Overman MJ, Maru M, Hamilton SR, Kopetz S. Association of PTEN loss and local recurrence in stage II-III colon cancer. J Clin Oncol 29((suppl 4; abstr 399)), 2011.
26. Kopetz S, Tran HT, Cunningham D, Mookerjee B, Pike L, Jurgensmeier J, Heymach J. Association of circulating cytokine and angiogenic factors (CAFs) with outcomes to second-line FOLFOX plus bevacizumab or cediranib in metastatic colorectal cancer. J Clin Oncol 29((suppl 4; abstr 406)), 2011.
27. Hassabo H, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR. Retrospective evaluation of patients with colorectal cancer (CRC) and type II non-insulin-dependent diabetes (NIDDM). J Clin Oncol 29((suppl 4; abstr 507)), 2011.
28. George B, You Y, Viswanathan C, Wen S, Baladandayuthapani V, Overman MJ, Kee BK, Kopetz S, Eng C, Garrett CR. Survival advantage associated with palliative oophorectomy in patients with metastatic colorectal cancer (CRC) to the ovaries (mCRC-O): A single institution retrospective analysis. J Clin Oncol 29((suppl 4; abstr 539)), 2011.
29. Ferrarotto R, Machado KK, Mak MP, Vieira VA, Takahashi TK, Saragiotto DF, Kopetz S, Overman MJ, Hoff PM. A multicenter, multinational retrospective analysis of mitomycin C (MMC) in refractory metastatic colorectal cancer (mCRC). J Clin Oncol 29, 2011.
30. Lieu CJ, Tran HT, Fiorentino S, Jiang Z, Mao M, Overman MJ, Eng C, Ellis LM, Heymach J, Kopetz S. Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer. J Clin Oncol 29, 2011.
31. Hassabo HM, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR. Survival advantage associated with metformin usage in patients with colorectal cancer (CRC) and type II noninsulin-dependent diabetes (NIDDM). J Clin Oncol 29, 2011.
32. Lieu CH, Tran HT, Jiang Z, Mao M, Overman MJ, Eng C, Morris J, Ellis LM, Heymach J, Kopetz S. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. J Clin Oncol 29, 2011.
33. Hassabo H, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR. Retrospective evaluation of patients with colorectal cancer (CRC) and type II non-insulin-dependent diabetes (NIDDM). J Clin Oncol 29, 2011.
34. Jiang Z, Mehta TR, You YN, Chang GJ, Eng C, Overman MJ, Maru D, Hamilton SR, Kopetz S. Association of PTEN loss and local recurrence in stage II-III colon cancer. J Clin Oncol 29, 2011.
35. George B, Estrella J, Machado L, Ferrarotto R, Hoff PM, Rashid A, Kopetz S. High-grade neuroendocrine carcinomas (HGNECs) of the colon and rectum: A single-institution retrospective analysis. J Clin Oncol 29, 2011.
36. George B, You YN, Viswanathan C, Wen S, Baladandayuthapani V, Overman MJ, Kee BK, Kopetz S, Eng C, Garrett CR. Survival advantage associated with palliative oophorectomy in patients with metastatic colorectal cancer (CRC) to the ovaries (mCRC-O): A single institution retrospective analysis. J Clin Oncol 29, 2011.
37. Chang G, Maru D, Agarwal A, Schlette E, Wolff R, Rodriguez-Bigas M, You N, Feig B, Kopetz S, Skibber J, Eng C. Histopathologic responses in primary tumors of patients with metastatic colorectal carcinoma after neoadjuvant systemic chemotherapy alone. Annals of Oncology, 2010.
38. Chang G, Maru D, Agarwal A,Schlette E, Wolff R, Rodriguez-Bigas M, You N, Feig B, Kopetz S, Skibber J, Eng C.. Histopathologic responses in primary tumors of patients with metastatic colorectal carcinoma after neoadjuvant systemic chemotherapy alone. 12th World Congress on Gastrointestinal Cancer, 2010.
39. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Lee R.J., Nolop KB, Bhattacharya S, Saltz L.. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. ASCO 2010, 2010.
40. Tran B, Kopetz S, Tie Jeanne, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J.. Distinct Differences in Sites of Metastatic Disease May Contribute to Poorer Outcomes Observed in Patients with BRAF Mutant Colorectal Cancers. ASCO 2010, 2010.
41. Agarwal A, Kopetz S, Boonsirikamchai P, Chun YS, Wang H, Vauthey JN, Loyer EM, Maru DM.. Tumor Thickness at Tumor-Normal Interface (TNI): A Novel Pathologic Indicator of Chemotherapy Response in Hepatic Colorectal Metastases (HCRM). United States and Canadian Academy of Pathology (USCAP), 2010.
42. Lieu CH, Wolff RA, Eng C, Overman MJ,Henry L, Coulson R, Garrett CR, Abbruzzese JL, Gallick GE, Kopetz S. Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer. J Clin Oncol 28(7), 2010.
43. Tran B, Kopetz S, Tie J, Gibbs P, Jiang Z, Lieu CH, Agarwal A, Maru D, Sieber O, Desai J. Differences in sites of metastatic disease and outcomes observed in patients with BRAF mutant colorectal cancers. J Clin Oncol 28, 2010.
44. Boonsirikamchai P, Maru DM, Chun YS, Kaur H, Kopetz S, Loyer EM. New CT Findings of Response and Recurrence Independent of Change in Tumor Size in Colorectal Liver Metastasis Treated with Bevacizumab. presented at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Chicago, 2009.
45. Pozadzides K, Wang H, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Overman MJ. Immunophenotype and molecular characterization of small bowel adenocarcinoma. Gastrointestinal Cancers Symposium, 2009.
46. Kopetz S, Hoff P, Eng C, Overman MJ, Glover KY, Chang DZ, Wolff RA, Abbruzzese JL, Ellis LM, Heymach JV. Levels of angiogenic cytokines prior to disease progression in metastatic colorectal cancer patients treated with bevacizumab. Gastointestinal Cancers Symposium:292, 2009.
47. Chun YS, Kopetz S, Palavecino M, Zorzi D, Curley SA, Abdalla EK, Vauthey JN. Proposal of new staging in advanced colorectal cancer. Gastrointestinal Cancers Symposium:304, 2009.
48. Sankhala K, Takimoto C, Mita A, Xiong H, Rodon JA, Adinin R, Burns K, Toko T, Arakawa K, Kopetz S. Two Phase I, Pharmacokinetic (PK) and Pharmacodynamic (PD) Studies of TAS-109, a novel nucleoside analogue with 14 days and 7 days continuous infusion (CI) schedules. ASCO 2008, 2008.
49. Kopetz S, Wolff R, Eng C, Henry L, Glover K, Chang D, Overman M, Gallick G, Abbruzzese J.. Phase IB study of Src inhibitation with dasatinib in combination with 5-fluorouracil, leuvocorin, oxaliplatin (FOLFOX) and cetuximab in metastatic colorectal cancer. AACR Meeting Abstracts:LB-69, 2008.
50. Eng C, Kopetz S, Morris J, Malik Z, Stewart D, Chang H, Ohinata A, Abbruzzese J, Gallick G.. Phase II study of the novel oral Src-kinase inhibitor, AZD0530, in previously treated advanced colorectal cancer patients. AACR Meeting Abstracts:LB-76, 2008.
51. Kopetz S. Phase I study of Src inhibition with dasatinib in combination with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) and cetuximab in metastatic colorectal cancer. 2008 ASCO Gastrointestinal Cancers Symposium, 2008.
52. Kopetz S, Mita MM, Sankhala KK, Moseley J, Sherman BM, Bradley CR, Tolcher AW.. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. 2008 ASCO Annual Meeting, 2008.
53. Politano S, Pathak P, Hoff PM, Charnsangavej C, Overman MJ, Loyer E, Vauthey J, Wallace MJ, Wolff RA, Kopetz S.. The use of 5-fluorouracil and oxaliplatin (FOLFOX) for colorectal cancer is associated with the development of splenomegaly and thrombocytopenia. 2008 ASCO Annual Meeting, 2008.
54. Kopetz S, Shah AN, Gallick GE. Src Continues Aging: Current and Future Clinical Directions. Clinical Cancer Research:7232, 2007.
55. Kopetz S, Wu J, Davies M, Johnson F, Donato N. Synergistic effects of combination therapy with anti-EGFR and anti-Src therapy in vitro in colon cancer. ASCO Gastrointestinal Cancers Symposium, 2007.
56. Kopetz S, Wu J, Davies M, Parikh N, Johnson F, Gallick G, Donato N.. Synergistic activity of Src and EGFR inhibitors in colon cancer. AACR Annual Meeting, 2007.
57. Kopetz S. Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer. 2007 ASCO Annual Meeting, 2007.
58. Chang D, Zhu K, Kopetz S, Voo K, Li Y, Hwu P, Radvanyi L, Abbruzzese JL. Presence of survivin-specific cytotoxic T-lymphocytes (CTLs) in pancreatic cancer patients, and specific killing of human pancreatic carcinoma cells in vitro by survivin-specific CTLs. 2007 ASCO Annual Meeting, 2007.
59. Kopetz S, Wu J, Johnson F, Donato N.. Anti-tumor effects of combination therapy with anti-EGFR and anti-Src therapy in colorectal cancer. AACR Meeting Abstracts:B51, 2006.
60. Hoff PM, Eng C, Adinin RB, Wolff RA, Lin E, Kopetz S, Rodney A, Chang DZ, Abbruzzese JL. Preliminary results from a phase II study of FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). Gastrointestinal Cancers Symposium, 2006.
61. Kopetz S, Dang J, Overman M, Phan L, Feig B, Patel D, Wolff RA, Eng CA, Abbruzzese JL, Hoff P. Bevacizumab toxicity and efficacy are unaffected by regimen or resection status: A single institution retrospective study. Gastrointestinal Cancers Symposium, 2006.
62. Kopetz S, Eng C, Adinin R, Wolff RA, Lin E, Chang DZ, Abbruzzese JL, Hoff PM. Preliminary results from a phase II study of FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). 2006 ASCO Annual Meeting, 2006.
63. Kopetz S, Eng C, Adinin RB, Wolff RA, Lin E, Chang DZ, Abbruzzese JL, Hoff PM. Preliminary results from a phase II study of FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). 2006 World GI Congress, 2006.
64. Dhillon N, Kopetz S, Del Fabbro E, Reddy S, Bruera E. The Establishment Of A Palliative Care Consult Team In A Comprehensive Cancer Center. 2005 ASCO Annual Meeting, 2005.
65. Galon J, Franck P, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Hartmann A, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 10(1):205. e-Pub 2012. PMID: 23034130.

Book Chapters

1. Hong DS, Kopetz ES, George GC. Colorectal Cancer (Adenocarcinoma). In: Handbook of Targeted Cancer Therapy. Wolters Kluwer Health, 2015.
2. Bhadkamkar N, Crane CH, Rodriguez-Bigas M, Kopetz S, Eng C. Colorectal Cancer. In: The MD Anderson Manual of Medical Oncology. 2nd, 2011.
3. Kopetz S. Targeted Therapy in Cancer. In: Targeted Therapy for Colorectal Cancer. Humana Press: United States, 101-24, 2008.
4. Hoff PMG, Kopetz S. Systemic Therapy for Non-operable Colorectal Cancer Metastases. In: Liver Metastases. Springer: United States of America, 51-8, 2008.
5. Kopetz S, Raber M, Abbruzzese J. Colorectal, Anal, and Unknown Primary Cancer (electronic web update). In: Cancer Medicine, 2006.
6. Kopetz S, Hoff P. Management Issues in Patients Presenting with Stage IV Colorectal Cancer. In: Advanced Therapy in Surgical Oncology. Decker Press, 281-91, 2006.

Letters to the Editor

1. Vauthey JN, Zorzi D, Kopetz S, Abdalla EK, Kishi Y, Blazer DG, III. Reply to Colorectal hepatic metastases: adjuvant chemotherapy and survival by D. Gallagher et al. J Clin Oncol 27: e20-1, 2009.
2. Vauthey JN, Zorzi D, Kopetz S, Abdalla EK, Kishi Y, Blazer DG. Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival Reply. J Clin Oncol 27: E20-E21, 2009.
3. Kopetz S, Abbruzzese JL.. Hidden Biases in an Observational Study of Bevacizumab Beyond Progression. J Clin Oncol 27: 1732-3, 2009.
4. Overman M, Kopetz S. First-Line Therapeutic Strategies in Metastatic Colorectal Cancer The Davies/Goldberg Article Reviewed. Oncology, New York-New York 22: 1482-1483, 2008.